---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-033507"
form_type: "8-K"
ticker: "FATE"
cik: "0001434316"
company_name: "FATE THERAPEUTICS INC"
filed_at: "2025-03-05T23:59:59+00:00"
generated_at: "2026-05-25T09:55:16.084451+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Fate Therapeutics: $306.7M cash runway through YE26; FT819 Phase 1 dose expansion in SLE underway

## Summary
- Cash, cash equivalents and investments of $306.7M; projected operating runway through year-end 2026.
- Initiated Phase 1 dose expansion of FT819 CAR T in SLE with flu-free conditioning (bendamustine or cyclophosphamide alone).
- First SLE patient treated with FT819 as add-on to maintenance therapy without conditioning; no DLTs, CRS, or ICANS.
- Completed Type D meeting with FDA to allow FT819 expansion into AAV, IIM, SSc; multi-dose and re-treatment permitted.
- Q4 total operating expenses $63.6M, including $14.7M non-cash impairment; revenue $1.9M from Ono collaboration.

## SEC filing metadata
- accession: 0000950170-25-033507
- form_type: 8-K
- ticker: FATE
- cik: 0001434316
- company_name: FATE THERAPEUTICS INC
- filed_at: 2025-03-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434316/000095017025033507/0000950170-25-033507-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434316/000095017025033507/fate-20250305.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-033507
- JSON: https://secwatch.observer/filing/0000950170-25-033507.json
- Plain text: https://secwatch.observer/filing/0000950170-25-033507.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.